Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 35,700 shares, a growth of 97.2% from the June 30th total of 18,100 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily volume of 32,500 shares, the short-interest ratio is currently 1.1 days.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Cocrystal Pharma in a research note on Tuesday, May 14th.
Get Our Latest Stock Report on COCP
Cocrystal Pharma Stock Down 0.9 %
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.15. On average, equities analysts predict that Cocrystal Pharma will post -2.02 EPS for the current fiscal year.
About Cocrystal Pharma
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Featured Stories
- Five stocks we like better than Cocrystal Pharma
- 3 Warren Buffett Stocks to Buy Now
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What is a SEC Filing?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Stock Sentiment Analysis: How it Works
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.